Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BIIB

Biogen Inc

Dec 08 • 04:00PM ET

239.29

Dollar change +0.17
Percentage change 0.07	%

Healthcare • Drug Manufacturers - General • USA • NASD

Stock Detail • Compare Perf. • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	NDX, S&P 500	P/E	23.79	EPS (ttm)	10.06	Insider Own	0.61%	Shs Outstand	144.10M	Perf Week	1.98%
Market Cap	34.67B	Forward P/E	15.14	EPS next Y	15.80	Insider Trans	-0.06%	Shs Float	144.02M	Perf Month	3.28%
Income	1.46B	PEG	158.61	EPS next Q	3.16	Inst Own	87.22%	Short Float / Ratio	1.83% / 2.69	Perf Quarter	-7.58%
Sales	9.61B	P/S	3.61	EPS this Y	-15.30%	Inst Trans	0.83%	Short Interest	2.63M	Perf Half Y	-22.53%
Book/sh	99.96	P/B	2.39	EPS next Y	5.58%	ROA	5.51%	Target Price	317.30	Perf Year	-17.90%
Cash/sh	15.79	P/C	15.15	EPS next 5Y	0.15%	ROE	10.73%	52W Range	220.86 - 319.76	Perf YTD	-13.59%
Dividend	-	P/FCF	32.66	EPS past 5Y	11.85%	ROI	6.74%	52W High	-25.17%	Beta	0.03
Dividend %	-	Quick Ratio	1.09	Sales past 5Y	-2.56%	Gross Margin	67.95%	52W Low	8.34%	ATR	5.18
Employees	8725	Current Ratio	1.68	Sales Q/Q	6.20%	Oper. Margin	17.89%	RSI (14)	55.06	Volatility	1.90% 2.06%
Optionable	Yes	Debt/Eq	0.53	EPS Q/Q	-106.00%	Profit Margin	15.21%	Rel Volume	0.98	Prev Close	239.12
Shortable	Yes	LT Debt/Eq	0.50	Earnings	Nov 08 BMO	Payout	0.00%	Avg Volume	978.18K	Price	239.29
Recom	1.55	SMA20	4.05%	SMA50	-1.85%	SMA200	-11.66%	Volume	955,632	Change	0.07%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327
Jul-24-23	Reiterated	UBS	Buy	$346 → $335
May-01-23	Upgrade	Guggenheim	Neutral → Buy	$270 → $350
Apr-17-23	Upgrade	Piper Sandler	Neutral → Overweight	$280 → $346
Oct-26-22	Upgrade	Goldman	Neutral → Buy	$220 → $370
Oct-13-22	Upgrade	Stifel	Hold → Buy	$223 → $299
Oct-07-22	Upgrade	Argus	Hold → Buy	$300
Sep-28-22	Upgrade	Robert W. Baird	Neutral → Outperform	$224 → $340
Sep-28-22	Upgrade	Mizuho	Neutral → Buy	$207 → $270
Sep-28-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$217 → $360
Apr-18-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$235 → $265
Mar-08-22	Downgrade	Stifel	Buy → Hold	$304 → $223
Mar-03-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$227 → $248
Feb-04-22	Reiterated	Wolfe Research	Peer Perform	$244 → $217
Feb-04-22	Reiterated	Wells Fargo	Equal Weight	$284 → $235
Feb-04-22	Reiterated	Wedbush	Neutral	$195 → $185
Feb-04-22	Reiterated	Robert W. Baird	Neutral	$258 → $224
Feb-04-22	Reiterated	RBC Capital Mkts	Sector Perform	$225 → $227

Show Previous Ratings

Today 11:30AM	Why Is Biogen Inc. (BIIB) Up 6.4% Since Last Earnings Report? (Zacks)
Dec-07-23 09:49AM	Biogen upgraded, Take-Two downgraded: Wall Street's top analyst calls (The Fly)
12:17AM	UNH, HUM, BIIB: 3 Healthcare Stocks to Buy, Say Analysts (TipRanks)
Dec-05-23 11:01AM	Billionaire Louis Bacons 10 Stock Picks with Huge Upside Potential (Insider Monkey)
Nov-29-23 08:35AM	Stocks To Buy And Watch: Top IPOs, Big And Small Caps, Growth Stocks (Investor's Business Daily)
03:14PM	Loading…
Nov-28-23 03:14PM	Is Eli Lilly Stock A Buy After Mounjaro Beats Out Ozempic In A Head-To-Head Analysis? (Investor's Business Daily)
05:53AM	Anaptys picks up rival to Biogen autoimmune asset from Centessa (FierceBiotech.com)
Nov-17-23 08:15AM	Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning (Investor's Business Daily)
Nov-13-23 09:48PM	Jim Simons Stock Portfolio: 5 Biggest Healthcare Stocks (Insider Monkey)
Nov-10-23 06:50AM	The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks? (Motley Fool)
Nov-09-23 04:27PM	Biogen Inc. (NASDAQ:BIIB) Q3 2023 Earnings Call Transcript (Insider Monkey)
03:49AM	Top 20 Drug Companies in the US by Revenue (Insider Monkey)
Nov-08-23 11:12PM	Q3 2023 Biogen Inc Earnings Call (Thomson Reuters StreetEvents) -5.67%
05:38PM	Analyst Report: Biogen Inc. (Morningstar Research)
04:04PM	Biogen Skids On 'Low-Quality' Beat, Cuts Profit Guidance Following Reata Buyout (Investor's Business Daily)
03:06PM	Loading…
03:06PM	Biogen Inc (BIIB) Reports Mixed Q3 2023 Results and Revises Full-Year Guidance (GuruFocus.com)
02:15PM	Biogen (BIIB) Q3 2023 Earnings Call Transcript (Motley Fool)
10:31AM	Biogen (BIIB) Beats on Q3 Earnings & Sales, Cuts EPS View (Zacks)
09:30AM	Compared to Estimates, Biogen Inc. (BIIB) Q3 Earnings: A Look at Key Metrics (Zacks)
08:40AM	Biogen Expects Sales of Alzheimers Drug Leqembi to Start Growing Next Year (The Wall Street Journal)
07:59AM	Biogens Earnings Top Estimates. Wall Street Still Has Questions About Growth. (Barrons.com)
07:03AM	Biogen cuts profit forecast on Alzheimer's drug launch, deal costs (Reuters)
07:00AM	Biogen Tops Earnings Forecasts, But Cuts Profit Outlook As Leqembi Expenses Mount (Investor's Business Daily)
06:30AM	Biogen says growth is coming, but wont specify when (BioPharma Dive)
Nov-07-23 05:41PM	Biogen Reports Earnings Wednesday. Heres What to Expect. (Barrons.com)
12:40PM	UPDATE 1-Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 (Reuters)
08:44AM	Biogen-Sage Therapeutics postpartum depression pill priced at $15,900 (Reuters)
08:32AM	Why Biogen (BIIB) Might Surprise This Earnings Season (Zacks)
06:30AM	Biogen, Sage set price of postpartum depression pill at $15,900 (BioPharma Dive)
Nov-06-23 12:02PM	Countdown to Biogen Inc. (BIIB) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS (Zacks)
08:26AM	Loading…
08:26AM	Biogen (BIIB) to Report Q3 Earnings: Will It Beat Estimates? (Zacks)
07:30AM	Biogen Appoints Monish Patolawala to its Board of Directors (GlobeNewswire)
Nov-03-23 09:44AM	Ionis (IONS) Q3 Loss Wider Than Expected, Sales Beat Estimates (Zacks)
05:09AM	Q3 2023 Ionis Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-01-23 10:01AM	Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-30-23 05:45PM	Biogen Inc. (BIIB) Rises But Trails Market: What Investors Should Know (Zacks)
Oct-27-23 12:45PM	Eli Lilly Gives Back Its Recent Weight-Loss Gains Is Lilly Stock A Buy? (Investor's Business Daily)
08:30AM	Alzheimer's drug Leqembi: The twice-monthly infusion could be available in injection form (Yahoo Finance)
08:30AM	Alzheimer drug Leqembi: the twice-monthly infusion could be available in injection form (Yahoo Finance)
Oct-26-23 04:09PM	Biogen Pulls Prothena Into A Steep Dive On Mixed Results For Alzheimer's Treatment (Investor's Business Daily)
10:35AM	Biogen and Eisais Revised Alzheimers Drug Works, but Safety Questions Linger (Barrons.com)
05:18AM	Alnylam, Biogen silence genes, building noise behind data on new approaches to Alzheimer's (FierceBiotech.com)
Oct-25-23 05:26PM	Eisai Presents New LEQEMBI® (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimers Disease From Additional Analyses of Clarity AD at The Clinical Trials On Alzheimers Disease (CTAD) Conference (GlobeNewswire)
05:25PM	Injected version of Eisai/Biogen Alzheimer's drug effective, side effects higher (Reuters)
10:51AM	New Data from Biogens Investigational Antisense Oligonucleotide (ASO) Targeting Tau Shows Promise for Potential New Generation of Treatments in Early Alzheimers Disease (GlobeNewswire)
Oct-24-23 09:30AM	LEQEMBI® (lecanemab-irmb) NAMED ONE OF TIME's BEST INVENTIONS OF 2023 (PR Newswire)
Oct-23-23 05:50PM	Here's Why Biogen Inc. (BIIB) Fell More Than Broader Market (Zacks)
03:25PM	Roche settles US patent lawsuit against Biogen over blockbuster arthritis drug (Reuters)
Oct-20-23 11:09AM	Eli Lilly Sparks As Rival Novo Says Diabetes Drug Could Treat Kidney Disease But Is Lilly Stock A Buy? (Investor's Business Daily)
Oct-19-23 07:30AM	Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 Meeting (GlobeNewswire)
Oct-18-23 11:20AM	5 Biotech Stocks Set to Outpace Q3 Earnings Estimates (Zacks)
08:23AM	3 Struggling Stocks Investors Shouldn't Buy on the Dip (Motley Fool)
Oct-17-23 05:50PM	Biogen Inc. (BIIB) Falls More Steeply Than Broader Market: What Investors Need to Know (Zacks)
Oct-13-23 09:55AM	Wall Street Analysts See a 25.44% Upside in Biogen Inc. (BIIB): Can the Stock Really Move This High? (Zacks)
Oct-11-23 04:40PM	7 Low-Volatility Stocks to Buy if Youre a Concerned Investor (InvestorPlace)
12:10PM	Will Biogen Inc. (BIIB) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Oct-10-23 09:54AM	New Biogen research chief Grogan looks to apply biotechs' scrappiness to a pharma in flux (FierceBiotech.com)
Oct-09-23 05:50PM	Biogen Inc. (BIIB) Advances But Underperforms Market: Key Facts (Zacks)
Oct-04-23 05:30AM	How Much Will Your Medicare Part B Premiums Increase Next Year? (Motley Fool)
Oct-02-23 05:50PM	Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know (Zacks)
Sep-29-23 04:06PM	FDA Approves Biogen's TOFIDENCE (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA (GlobeNewswire)
Sep-28-23 01:16PM	Is Eli Lilly Stock A Buy Now That It Has Topped A Profit-Taking Zone? (Investor's Business Daily)
10:07AM	Is Biogen Stock a Buy Now? (Motley Fool)
10:06AM	Ionis (IONS) Inks New Deal With Roche to Develop Novel RNA Drugs (Zacks)
06:27AM	The Petri Dish: Ginkgo, Pfizer sign $331M deal; Leqembi OK'd in Japan (American City Business Journals)
Sep-27-23 09:58AM	Ionis (IONS) Meets Rare Disease Drug Study Goal, Stock Up 8.5% (Zacks)
Sep-26-23 08:59AM	Biogen Completes Acquisition of Reata Pharmaceuticals (GlobeNewswire)
02:18AM	After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen (AP Finance)
Sep-25-23 05:50PM	Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know (Zacks)
11:39AM	Unveiling Biogen (BIIB)'s Value: Is It Really Priced Right? A Comprehensive Guide (GuruFocus.com)
09:57AM	UPDATE 1-Japan approves Alzheimer's treatment Leqembi by Eisai and Biogen (Reuters)
01:13AM	Japan approves Alzheimer treatment Leqembi by Eisai and Biogen (Reuters)
01:02AM	LEQEMBI® Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimers Disease in Japan (GlobeNewswire)
Sep-20-23 10:02AM	GE Healthcare: Why it's still waiting on its Leqembi windfall (Yahoo Finance)
Sep-12-23 05:50PM	Biogen Inc. (BIIB) Stock Moves -0.19%: What You Should Know (Zacks)
Sep-09-23 07:45AM	Does Biogen's Latest $1.5 Billion-Dollar Move Make It a Buy? (Motley Fool)
Sep-08-23 12:10PM	Alector (ALEC) Up 7% on Finishing Enrolment in Alzheimer Study (Zacks)
09:24AM	The Zacks Analyst Blog Highlights Humana, Cintas, Biogen, Royal Caribbean Cruises and Markel Group (Zacks)
Sep-07-23 05:17PM	Top Analyst Reports for Humana, Cintas & Biogen (Zacks)
07:08AM	7 Pharma Stocks to Buy for Groundbreaking Treatments and Robust Revenue Growth (InvestorPlace)
06:30AM	The Petri Dish: Biogen secures $1.5B loan; Mersana CEO departs after trial failure (American City Business Journals)
Sep-06-23 05:50PM	Biogen Inc. (BIIB) Dips More Than Broader Markets: What You Should Know (Zacks)
11:16AM	Octave Bioscience Releases Multiple Sclerosis Study in Biogen Partnership (Exec Edge)
07:30AM	Biogen Appoints Jane Grogan as Head of Research (GlobeNewswire)
Sep-05-23 09:40AM	Biogen's (BIIB) Stock Outperforms Industry YTD: Here's Why (Zacks)
Sep-01-23 03:51PM	FDA Documents Suggest Sage's Battle In Depression Drugs Will Be Trickier Than Expected (Investor's Business Daily)
Aug-31-23 05:45PM	Biogen Inc. (BIIB) Gains As Market Dips: What You Should Know (Zacks)
11:10AM	Sage Therapeutics Cuts Workforce By 40% Following Rejection In Depression Treatment (Investor's Business Daily)
10:10AM	Sage cuts nearly half its staff in wake of partial FDA rejection (American City Business Journals)
07:00AM	UPDATE 1-Sage Therapeutics to cut about 188 jobs after depression drug setback (Reuters)
Aug-30-23 05:50PM	Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know (Zacks)
11:41AM	Eli Lilly Has A Big Stake In Weight Loss And Alzheimer's Drugs; But Is The Stock A Buy? (Investor's Business Daily)
Aug-29-23 11:39AM	Roche's (RHHBY) Evrysdi Gets Label Expansion in EU for Newborns (Zacks)
10:07AM	Better Buy: Biogen vs. Eli Lilly (Motley Fool)
Aug-28-23 10:57AM	Novartis' (NVS) Sandoz Gets FDA Nod for Tysabri's Biosimilar (Zacks)
09:39AM	12 Undervalued Wide Moat Stocks To Invest In (Insider Monkey)
Aug-25-23 12:17PM	Novartis comes for a Biogen MS drug with new biosimilar (American City Business Journals)
Aug-24-23 11:30AM	Biogen Inc. (BIIB) Down 0.2% Since Last Earnings Report: Can It Rebound? (Zacks)
Aug-17-23 04:54PM	Biogen's 1,000-person layoff begins in Cambridge (American City Business Journals)
Aug-16-23 11:08AM	CORRECTED-INSIGHT-What happens when a $2 million gene therapy is not enough (Reuters)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BIOGEN INC.	10% Owner	Sep 26	Sale	0.50	6,000,000	3,000,000	17,652,466	Sep 28 05:30 PM
Singhal Priya	Head of Development	Sep 05	Sale	269.43	431	116,124	3,354	Sep 06 06:06 PM
Singhal Priya	Head of Development	Sep 01	Option Exercise	0.00	1,668	0	4,592	Sep 06 06:06 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Sep 01	Option Exercise	0.00	5,285	0	14,060	Sep 06 06:08 PM
Singhal Priya	Head of Development	Jul 03	Sale	282.87	81	22,912	2,924	Jul 05 05:33 PM
Izzar Rachid	Head of Global Product Strat.	Jun 30	Option Exercise	0.00	504	0	6,388	Jul 05 05:37 PM
Kramer Robin	Chief Accounting Officer	Jun 30	Option Exercise	0.00	252	0	4,096	Jul 05 05:35 PM
Singhal Priya	Head of Development	Jun 30	Option Exercise	0.00	315	0	3,158	Jul 05 05:33 PM
Gregory Ginger	EVP, Human Resources	Apr 28	Sale	300.00	2,681	804,300	8,483	May 02 08:05 PM
Singhal Priya	Head of Development	Apr 04	Sale	277.11	91	25,217	2,843	Apr 06 06:37 PM
Murphy Nicole	Head of Pharm Ops and Tech	Mar 31	Option Exercise	0.00	239	0	5,818	Apr 04 05:21 PM
Singhal Priya	Head of Development	Mar 28	Sale	270.06	568	153,394	2,842	Mar 30 06:31 PM
Singhal Priya	Head of Development	Mar 02	Option Exercise	0.00	297	0	3,554	Mar 06 06:13 PM
Singhal Priya	Head of Development	Feb 17	Option Exercise	0.00	460	0	3,951	Feb 22 05:07 PM
Kramer Robin	Chief Accounting Officer	Feb 17	Option Exercise	0.00	512	0	3,844	Feb 22 05:01 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 17	Option Exercise	0.00	2,561	0	10,147	Feb 22 05:03 PM
Izzar Rachid	Head of Global Product Strat.	Feb 17	Option Exercise	0.00	767	0	5,884	Feb 22 04:57 PM
Gregory Ginger	EVP, Human Resources	Feb 17	Option Exercise	0.00	1,792	0	11,072	Feb 22 04:54 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Feb 17	Option Exercise	0.00	1,920	0	46,840	Feb 22 04:49 PM
ALEXANDER SUSAN H	EVP Chief Legal Off & Corp Sec	Feb 10	Option Exercise	0.00	4,023	0	48,358	Feb 14 09:46 PM
Gregory Ginger	EVP, Human Resources	Feb 10	Option Exercise	0.00	3,290	0	12,805	Feb 14 09:44 PM
Izzar Rachid	Head of Global Product Strat.	Feb 10	Option Exercise	0.00	1,968	0	6,359	Feb 14 09:41 PM
Kramer Robin	Chief Accounting Officer	Feb 10	Option Exercise	0.00	1,061	0	3,932	Feb 14 09:37 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 10	Option Exercise	0.00	3,256	0	10,001	Feb 14 09:25 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 10	Option Exercise	0.00	2,611	0	6,379	Feb 14 09:23 PM
Singhal Priya	Head of Development	Feb 10	Option Exercise	0.00	1,211	0	3,863	Feb 14 09:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIIB

Biogen Inc

Upgrade your FINVIZ experience